Filtros de búsqueda

Lista de obras de

A Phase II Study of Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory or Poor-Risk Acute Myeloid Leukemia Patients

artículo científico publicado en 2017

A multicenter phase I/II study of obatoclax mesylate administered as a 3- or 24-hour infusion in older patients with previously untreated acute myeloid leukemia

artículo científico publicado en 2014

A phase 1 dose-escalation study of ARRY-520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias

artículo científico publicado en 2011

A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia

artículo científico publicado en 2008

A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generat

artículo científico publicado en 2015

A phase I study of fludarabine, cytarabine, and oxaliplatin therapy in patients with relapsed or refractory acute myeloid leukemia

artículo científico publicado en 2014

A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies

artículo científico publicado en 2008

A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia

artículo científico publicado en 2017

A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia

artículo científico publicado en 2014

A phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities

artículo científico publicado en 2012

A phase II, multicenter, open-label study of obatoclax mesylate in patients with previously untreated myelodysplastic syndromes with anemia or thrombocytopenia

artículo científico publicado en 2014

A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia

artículo científico publicado en 2014

A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase

artículo científico publicado en 2016

A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia

artículo científico publicado en 2017

A randomized phase II study of low-dose decitabine versus low-dose azacitidine in lower risk MDS and MDS/MPN.

artículo científico publicado en 2017

A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome

artículo científico publicado en 2011

A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome

artículo científico publicado en 2008

A single case of rosai-dorfman disease marked by pathologic fractures, kidney failure, and liver cirrhosis treated with single-agent cladribine

artículo científico

ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies

artículo científico publicado en 2016

Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia

scientific article published on 23 July 2013

Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia

artículo científico publicado en 2012

Activation of p53 signaling by MI-63 induces apoptosis in acute myeloid leukemia cells

artículo científico publicado en 2010

Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine

artículo científico publicado en 2008

Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia

artículo científico publicado en 2007

Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies

artículo científico publicado en 2016

Acute pulmonary failure during remission induction chemotherapy in adults with acute myeloid leukemia or high-risk myelodysplastic syndrome

artículo científico publicado en 2010

Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation

artículo científico publicado en 2015

Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous Leukemia

artículo científico publicado en 2016

An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes

artículo científico publicado en 2017

An open-label phase 2 study of glycogen synthase kinase-3 inhibitor LY2090314 in patients with acute leukemia

artículo científico publicado en 2016

Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes

artículo científico publicado en 2016

Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs

Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months

artículo científico publicado en 2013

Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia.

artículo científico publicado en 2018

Biological and clinical features of trisomy 21 in adult patients with acute myeloid leukemia

artículo científico publicado en 2013

Blood counts at time of complete remission provide additional independent prognostic information in acute myeloid leukemia

artículo científico publicado en 2008

Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome

artículo científico publicado en 2015

Bromodomain inhibitors: what does the future hold?

Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias

scientific article published on 27 September 2016

Cause of death in patients with lower-risk myelodysplastic syndrome

artículo científico publicado en 2010

Challenges in surgical management of abdominal pain in the neutropenic cancer patient.

artículo científico publicado en 2008

Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR-ABL kinase domain mutations

artículo científico publicado en 2018

Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy

artículo científico publicado en 2008

Characteristics of Sweet Syndrome in patients with acute myeloid leukemia

artículo científico publicado en 2014

Characteristics of translocation (16;16)(p13;q22) acute myeloid leukemia

artículo científico publicado en 2012

Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance

artículo científico publicado en 2009

Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship

artículo científico publicado en 2016

Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia

artículo científico publicado en 2017

Clinical Outcomes in Adult Patients with Aplastic Anemia- a single institution experience

artículo científico

Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction

artículo científico publicado en 2015

Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS.

artículo científico publicado en 2012

Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis

artículo científico publicado en 2014

Clinical characteristics of Philadelphia positive T-cell lymphoid leukemias-(De novo and blast phase CML).

artículo científico publicado en 2016

Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients

artículo científico publicado en 2015

Clofarabine combinations as acute myeloid leukemia salvage therapy

artículo científico publicado en 2008

Clofarabine does not negatively impact the outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation

artículo científico publicado en 2012

Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients

scientific article published on 26 January 2012

Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia

artículo científico publicado en 2013

Clofarabine: emerging role in leukemias

artículo científico publicado en 2009

Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment

artículo científico publicado en 2017

Comparison of Multiparameter Flow Cytometry Immunophenotypic Analysis and Quantitative RT-PCR for the Detection of Minimal Residual Disease of Core Binding Factor Acute Myeloid Leukemia.

artículo científico publicado en 2016

Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors

artículo científico publicado en 2015

Core-binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I-CBFit)

Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia

artículo científico publicado en 2010

Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia

artículo científico publicado en 2010

Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia

artículo científico publicado en 2009

Decitabine can be safely reduced after achievement of best objective response in patients with myelodysplastic syndrome

artículo científico publicado en 2013

Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy

scientific article published on 15 April 2009

Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes

artículo científico publicado en 2015

Discovery and clinical introduction of first-in-class imipridone ONC201.

articulo cientifico

Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure

artículo científico publicado en 2009

Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype

artículo científico publicado en 2016

Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities

artículo científico publicado en 2013

Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy

artículo científico publicado en 2013

Emerging cell cycle inhibitors for acute myeloid leukemia

artículo científico publicado en 2017

Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia

artículo científico publicado en 2012

Erythroleukemia-historical perspectives and recent advances in diagnosis and management

artículo científico publicado en 2017

Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors

artículo científico publicado en 2015

Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial

artículo científico publicado en 2011

Extramedullary acute myeloid leukemia: leukemic pleural effusion, case report and review of the literature

artículo científico publicado en 2014

Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast

artículo científico publicado en 2009

Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia

artículo científico publicado en 2008

Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

artículo científico publicado en 2015

Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia

artículo científico publicado en 2015

Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen

artículo científico publicado en 2016

Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome

artículo científico publicado en 2012

First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia

artículo científico publicado en 2010

Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - a propensity score analysis

artículo científico publicado en 2016

Frontline treatment of acute myeloid leukemia in adults

artículo científico publicado en 2016

Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia

artículo científico publicado en 2014

HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia

artículo científico publicado en 2013

Hemostatic gene polymorphisms and the prevalence of thrombotic complications in polycythemia vera and essential thrombocythemia

artículo científico publicado en 2004

Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV).

artículo científico publicado en 2017

Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma

artículo científico publicado en 2017

Hypocellular acute myeloid leukemia in adults: analysis of the clinical outcome of 123 patients

artículo científico publicado en 2011

Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction

artículo científico publicado en 2010

Imatinib mesylate in the treatment of chronic myelogenous leukemia

artículo científico publicado en 2004

Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictors

artículo científico publicado en 2007

Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors

artículo científico publicado en 2016

Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents

artículo científico publicado en 2017

Impact of numerical variation in FMS-like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype acute myelogenous leukemia

artículo científico publicado en 2012

Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia

artículo científico publicado en 2011

Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers

artículo científico publicado en 2011

Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience

artículo científico publicado en 2012

Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade

artículo científico publicado en 2015

Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia ⬇️

Kinetics of bone marrow blasts during induction and achievement of complete remission in acute myeloid leukemia

artículo científico publicado en 2008

Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents

artículo científico publicado en 2014

Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?

scholarly article by Musa Yilmaz et al published 16 January 2019 in Blood Cancer Journal

Lenalidomide as a novel treatment of acute myeloid leukemia

artículo científico

Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting

artículo científico publicado en 2017

Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial.

artículo científico publicado en 2018

Localization of the adhesion receptor glycoprotein Ib-IX-V complex to lipid rafts is required for platelet adhesion and activation

scientific journal article

Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical tr

artículo científico publicado en 2015

Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab

artículo científico publicado en 2016

Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations

artículo científico publicado en 2009

Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib

artículo científico publicado en 2010

MDM2 Inhibitor, Nutlin 3a, Induces p53 Dependent Autophagy in Acute Leukemia by AMP Kinase Activation

artículo científico publicado en 2015

Mechanisms of apoptosis induction by simultaneous inhibition of PI3K and FLT3-ITD in AML cells in the hypoxic bone marrow microenvironment

artículo científico publicado en 2012

Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia

artículo científico publicado en 2015

Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia

artículo científico publicado en 2017

Modeling interactions between leukemia-specific chromosomal changes, somatic mutations, and gene expression patterns during progression of core-binding factor leukemias

artículo científico publicado en 2010

More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia.

artículo científico publicado en 2017

Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse

artículo científico publicado en 2013

Myeloid neoplasms after breast cancer: "therapy-related" not an independent poor prognostic factor

artículo científico publicado en 2014

Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents

artículo científico publicado en 2017

New Tool for Monitoring Molecular Response in Patients With Chronic Myeloid Leukemia

artículo científico publicado en 2017

Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase

artículo científico publicado en 2009

Ocular granulocytic sarcoma: a case report and literature review of ocular extramedullary acute myeloid leukemia

artículo científico publicado en 2012

Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome

artículo científico publicado en 2010

Outcome after failure of second generation tyrosine kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemia

artículo científico publicado en 2013

Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia

artículo científico publicado en 2016

Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy

artículo científico publicado en 2011

Outcomes of Patients With Relapsed Core Binding Factor-Positive Acute Myeloid Leukemia

artículo científico publicado en 2017

Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia

artículo científico publicado en 2018

Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML).

artículo científico publicado en 2016

Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience

artículo científico publicado en 2013

Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial

artículo científico publicado en 2017

Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera

artículo científico publicado en 2009

Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia

artículo científico publicado en 2016

Pharmacokinetics of posaconazole prophylaxis of patients with acute myeloid leukemia

artículo científico publicado en 2015

Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies

artículo científico publicado en 2017

Phase 1 study of XL119, a rebeccamycin analog, in patients with refractory hematologic malignancies

artículo científico publicado en 2008

Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies

artículo científico publicado en 2012

Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia

artículo científico publicado en 2011

Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation

artículo científico publicado en 2013

Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher-risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents

artículo científico publicado en 2016

Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia

artículo científico publicado en 2012

Phase I and extension study of clofarabine plus cyclophosphamide in patients with relapsed/refractory acute lymphoblastic leukemia

artículo científico publicado en 2013

Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies

artículo científico publicado en 2015

Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemia

artículo científico publicado en 2016

Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status

artículo científico publicado en 2013

Phase I study of sorafenib in patients with refractory or relapsed acute leukemias

artículo científico publicado en 2010

Phase I-II study of bendamustine in patients with acute leukemia and high risk myelodysplastic syndrome

artículo científico publicado en 2012

Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia

artículo científico publicado en 2010

Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia

artículo científico publicado en 2015

Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia

artículo científico publicado en 2009

Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome

artículo científico publicado en 2015

Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia

artículo científico publicado en 2014

Phase II study of sunitinib in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis

artículo científico publicado en 2010

Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome

artículo científico publicado en 2011

Phase II trial of homoharringtonine with imatinib in chronic, accelerated, and blast phase chronic myeloid leukemia

artículo científico publicado en 2017

Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome

artículo científico publicado en 2012

Phase II, open label, randomized comparative trial of ondansetron alone versus the combination of ondansetron and aprepitant for the prevention of nausea and vomiting in patients with hematologic malignancies receiving regimens containing high-dose c

Phosphorylation of GSK3α/β correlates with activation of AKT and is prognostic for poor overall survival in acute myeloid leukemia patients

artículo científico publicado en 2015

Pilot study of bortezomib for patients with imatinib-refractory chronic myeloid leukemia in chronic or accelerated phase

artículo científico publicado en 2011

Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy

artículo científico publicado en 2006

Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study

artículo científico publicado en 2015

Precision 're'arming of CD33 antibodies

artículo científico publicado en 2013

Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia

scientific article published on 28 February 2014

Predicting survival of patients with hypocellular myelodysplastic syndrome: development of a disease-specific prognostic score system

artículo científico publicado en 2012

Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase

artículo científico publicado en 2017

Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment

artículo científico publicado en 2011

Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure

artículo científico publicado en 2010

Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel

artículo científico publicado en 2011

Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients

artículo científico publicado en 2017

Prognostic impact of RAS mutations in patients with myelodysplastic syndrome

artículo científico publicado en 2013

Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia

artículo científico publicado en 2016

Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease

artículo científico publicado en 2016

Prognostic implications of chromosome 17 abnormalities in the context of monosomal karyotype in patients with acute myeloid leukemia and complex cytogenetics

artículo científico publicado en 2014

Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors

artículo científico publicado en 2017

Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in acute myeloid leukaemia

artículo científico publicado en 2015

Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia

artículo científico publicado en 2010

Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104

artículo científico publicado en 2011

REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia

artículo científico publicado en 2014

RUNX3 promoter hypermethylation is frequent in leukaemia cell lines and associated with acute myeloid leukaemia inv(16) subtype

artículo científico publicado en 2015

Randomized comparison of cooked and noncooked diets in patients undergoing remission induction therapy for acute myeloid leukemia

artículo científico publicado en 2008

Randomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes

artículo científico publicado en 2013

Relapse and death during first remission in acute myeloid leukemia

artículo científico publicado en 2008

Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials

artículo científico publicado en 2015

Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes

artículo científico publicado en 2010

Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia

artículo científico publicado en 2009

Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia

artículo científico publicado en 2014

Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies

artículo científico publicado en 2014

Role of rituximab in first-line treatment of chronic lymphocytic leukemia ⬇️

artículo científico publicado el 22 de diciembre de 2010

Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis

scientific article published on 18 June 2015

Safety and clinical activity of 5-aza-2'-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed/refractory acute lymphocytic leukaemia

artículo científico publicado en 2014

Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD

artículo científico publicado en 2013

Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia

artículo científico publicado en 2013

Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study

scientific article published on 22 December 2014

Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors

artículo científico publicado en 2013

Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase

artículo científico publicado en 2009

Similar outcome of patients with chronic myeloid leukemia treated with imatinib in or out of clinical trials

artículo científico publicado en 2013

Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial

artículo científico publicado en 2018

Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I.

artículo científico publicado en 2010

Successful Treatment of Intracranial Hemorrhage with Recombinant Activated Factor VII in a Patient with Newly Diagnosed Acute Myeloid Leukemia: A Case Report and Review of the Literature

artículo científico publicado en 2015

Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells

scholarly article by Warren Fiskus et al published 15 January 2019 in Blood Cancer Journal

Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities

artículo científico publicado en 2009

Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia

artículo científico publicado en 2009

Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy

artículo científico publicado en 2010

TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens

artículo científico publicado en 2017

TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes

artículo científico publicado en 2016

Targeting autophagy to overcome chemoresistance in acute myleogenous leukemia

artículo científico publicado en 2016

The Dual MEK/FLT3 Inhibitor E6201 Exerts Cytotoxic Activity against Acute Myeloid Leukemia Cells Harboring Resistance-Conferring FLT3 Mutations

artículo científico publicado en 2016

The association between opioid administration and response to therapy in patients with acute lymphoblastic leukemia

artículo científico publicado en 2015

The clinical significance of achieving different levels of cytogenetic response in patients with chronic phase chronic myeloid leukemia after failure to front-line therapy: is complete cytogenetic response the only desirable endpoint?

artículo científico publicado en 2011

The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: how does it relate to the original lenalidomide experience in MDS?

artículo científico publicado en 2009

Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase

artículo científico publicado en 2015

Therapy of acute myelogenous leukemia in adults

artículo científico publicado en 2010

Therapy of core binding factor acute myeloid leukemia: incremental improvements toward better long-term results

artículo científico publicado en 2012

Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis

artículo científico publicado en 2012

Therapy-related acute myelogenous leukemia and myelodysplastic syndrome

artículo científico publicado en 2007

Time to response and survival in hypomethylating agent-treated acute myeloid leukemia

artículo científico publicado en 2017

Transglutaminase 2 expression in acute myeloid leukemia: association with adhesion molecule expression and leukemic blast motility

artículo científico publicado en 2013

Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival

artículo científico publicado en 2008

Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations

artículo científico publicado en 2014

Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for Patients with Chronic Myelomonocytic Leukemia

artículo científico publicado en 2015

Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia

artículo científico publicado en 2012

Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience

scholarly article by Kamal Chamoun et al published 3 January 2019 in Journal of Hematology & Oncology

Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase

artículo científico publicado en 2013

Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome

artículo científico publicado en 2017

XIAP antisense oligonucleotide (AEG35156) achieves target knockdown and induces apoptosis preferentially in CD34+38− cells in a phase 1/2 study of patients with relapsed/refractory AML ⬇️

artículo científico publicado el 1 de enero de 2011

XIAP antisense therapy with AEG 35156 in acute myeloid leukemia

artículo científico publicado en 2013

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda